期刊文献+

腹腔内全身新辅助化疗(双向化疗)对胃癌腹膜转移癌患者的疗效研究 被引量:3

Effects of Neoadjuvant Systemic/Intraperitoneal Chemotherapy(Bidirectional Chemotherapy)on Peritoneal Carcinomatosis of Gastric Cancer
下载PDF
导出
摘要 目的:建立联合腹腔内-全身新辅助化疗方案(NIPS)和腹膜切除术的新型多学科交叉治疗模式。方法:2004年4月至2011年12月本研究纳入来自日本大阪草津综合病院和岸和田综合病院的胃癌腹膜转移癌患者96例,在NIPS治疗前后,均通过腹腔导管系统进行了腹腔冲洗液细胞学检查。患者每日按60 mg/m^2剂量口服S-1,持续21天,随后休息一周;在第1、8、15 d,分别通过腹腔导管给予多西他赛30mg/m^2和顺铂30mg/m^2(500mL生理盐水稀释)。术前行2个周期NIPS。NIPS后3周,82例患者符合意向性细胞减灭术(CRS),即进行胃切除术+D2根治术+腹膜切除术获得完全细胞减灭。结果:68例在NIPS之前细胞学检查阳性,其中47例(69.1%)在NIPS之后细胞学检查阴性,30例(36.8%)在NIPS治疗后达到病理学完全缓解,12例(14.6%)患者达到肿瘤分期下降,58例(70.7%)达到完全细胞减灭。9例患者出现4级并发症,总体手术死亡率为3.7%(3/82)。多变量分析显示,完全细胞减灭和病理缓解是改善患者生存的独立预后因素。结论:该疗法的最佳适应症为病理缓解良好,PCI评分≤6,预期可以通过腹膜切除术达到完全细胞减灭。 Objective:This study aimed to develop a novel multidisciplinary treatment strategy combining neoadjuvant intraperi -toneal-systemic chemotherapy protocol (NIPS) and peritonectomy. Methods:Gastric cancer patients with peritoneal carcinomatosis (PC) ( n=96) were enrolled. Peritoneal wash cytology was performed before and after NIPS through a port system. For systemic chemo -therapy, the patients were treated with 60mg/m2 of oral S- 1 for 21d, followed by a 1-week rest. For intraperitoneal chemotherapy, 30mg/m2 of Docetaxel and 30mg/m2 of cisplatin with 500 mL of saline were introduced through the port on d 1, 8, and 15. Two cycles of the NIPS regimen was conducted before surgery. Three weeks after NIPS, 82eligible patients underwent complete cytoreductive sur-gery (CRS) by gastrectomy plus D 2 dissection and peritonectomy. Results:Positive cytologic result was observed in 68patients treated with peritoneal washing before NIPS. The number was reduced to 47(69.1%) after NIPS. After NIPS, complete pathologic response on PC was observed in 30(36.8% ) patients. Reduction of tumor stages occurred in12patients ( 14.6% ). Complete cyto-reduction was achieved in 58of the total patients (70.7%). Grade4 toxicities occurred in 9 cases, and the overall perioperative mortality rate was 3.7% (3/82). By multivariate analysis, complete cytoreduction and pathologic response were found to be independent factors for achieving a satisfactory survival rate. Conclusion:The optimal candidates for such multidisciplinary approach are patients with favorable patholog -ic response and PCI ≤6, among whom complete CRS could be achieved with peritonectomy.
作者 米村豊
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第22期1699-1705,共7页 Chinese Journal of Clinical Oncology
关键词 腹膜转移癌 胃癌预后新辅助化疗 肿瘤细胞减灭术 Peritoneal carcinomatosis Gastric cancer Prognosis Neoadjuvant chemotherapy Cytoreductive surgery
  • 相关文献

参考文献24

  • 1Gill RS, Ai-Adra DP, Nagendran J, et al. Treatment of Gastric Cancer With Peritoneal Carcinomatosis by Cytoreductive Surgery and HIPEC: A Systematic Review of Survival, Mortality, and Mor- bidity[]].J Surg Oncol, 2011, 104(6):692-698.
  • 2Preusser P, Wilke H, Achterrath W, et al. Phase 1I study with the combination etoposide, doxorubicin, and cisplatin in advanced mea- surable gastric cancer[]].J Clin Oncol, 1989, 7(9):1310-1317.
  • 3AjaniJA, Ota DM, Jessup JM, et al. Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy[J].Cancer, 1991, 68(7):1501-1506.
  • 4Yang XJ, Huang CQ Suo T, et al. Cytoreductive Surgery and Hy- perthermic Intraperitoneal Chemotherapy Improves Survival of Pa- tients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase II Randomized Clinical TriM[J].Ann Surg On- col,2011, 18(6):1575-1581.
  • 5Yonemura Y, Bandou E, Kinoshita K, et al. Effective therapy for peritoneal dissemination in gastric cancer[J].Surg Oncol Clin N Am, 2003, 12(3):635-648.
  • 6Sugarbaker PH, Yonemura Y. Clinical pathway for the manage- ment of resectable gastric cancer with peritoneal seeding: best pallia- tion with a ray of hope for cure[J].Oncology, 2000, 58 (2):96-107.
  • 7Yonemura Y, Endou Y, Shinbo M. Safety and efficacy of bidirec- tional chemotherapy for treatment of patients with peritoneal dis- semination from gastric cancer: selection for cytoreductive surgery[J].J Surgl Oncol, 2009, 100(4):311-316.
  • 8Yonemura Y, Bandou E, Kawamura T, et al. Ouantitative prognos- tic indicators of peritoneal dissemination of gastric cancer[J]. Eur J Surg Oncol, 2006, 32(6):602-606.
  • 9Sugarbaker TS, Chang D, Koslowe P, et al. Patterns of spread of re- current intraabdominal sarcoma. Peritoneal carcinomatosis: 4, in Peritoneal Carcinomatosis-4 Principles of Management[M]. P. H. Sugarbaker, Ed. Kluwer Academic Publisher, 1996:65-78.
  • 10Weber T, Roitman M, Link KH. Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Pa- tients With Peritoneal Carcinomatosis From Colorectal Cancer[J]. Clin Colorectal Can. 2012, 11 (3):167-176.

同被引文献22

  • 1孙晓卫,詹友庆,李威,徐立,李锦添,陈小君,张如华,徐大志.新辅助化疗对胃癌微卫星不稳定性的影响[J].癌症,2006,25(12):1493-1496. 被引量:5
  • 2Satoru M,Tomoo S,Masao H. A case of solitary splen-ic sarcoid reactions with advanced gastric cancer[J].Turk J Gastroenterol,2012,(06):810-811.
  • 3Vanis N;Mesihovi蔽R;Ibricevi L.Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma[J],{H}Collegium Antropologicum2013(01):291-297.
  • 4Noguès C,Mouret-Fourme E. Prophylactic surgery in com-mon hereditary cancer syndromes[J].{H}Bulletin de L Académie Nationale de Médecine,2012,(07):1237-1245.
  • 5Suzuki K,Noda Y,Fujita N. Clinicopathological study on endocrine cell micronests associated with early gastric cancer[J].{H}Internal Medicine,2013,(12):1311-1316.
  • 6Ishida M,Sekine S,Fukagawa T. Neuroendocrine car-cinoma of the stomach:morphologic and immunohistochemi-cal characteristics and prognosis[J].{H}American Journal of Surgical Pathology,2013,(07):949-959.PMID:23759931.
  • 7周东雷.FOLFOX7新辅助化疗对进展期胃癌治疗策略的影响[D].广州:第二军医大学,2012.
  • 8杨酷,王治国.多西他赛联合顺铂、氟尿嘧啶和亚叶酸钙的新辅助化疗方案治疗不能切除进展期胃癌的疗效观察[J].中国医学创新,2011,8(33):46-50.
  • 9贺岭风,杨克虎,田金徽,拜争刚.胃癌新辅助化疗疗效的系统评价——Meta分析[J].癌症,2008,27(4):407-412. 被引量:37
  • 10李闯,张跃伟.区域动脉灌注联合腹腔内化疗及热疗治疗进展期胃癌疗效学观察[J].当代医学,2009,15(17):317-318. 被引量:1

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部